President Donald Trump announced an expansion of TrumpRx.gov that will add more than 600 generic medications to the platform, aiming to increase transparency and competition in prescription drug pricing for American consumers.
According to a fact sheet released by the White House, the expanded platform will allow Americans to compare cash prices for generic medications across multiple pharmacy discount programs and local pharmacies without relying on insurance intermediaries.
The administration said the updated platform will integrate discounts and pricing information from major pharmacy savings providers, including Amazon Pharmacy, Cost Plus Drugs, and GoodRx. Patients will also be able to compare those cash prices against co-pays offered through their insurance plans.
The White House said the platform is designed to encourage greater price competition among pharmacy discount companies by consolidating pricing information in one location for consumers.
The generic medications listed on the platform will be separate from the discounts on branded medications that the administration said were negotiated through President Trump’s Most-Favored-Nation drug pricing agreements.
The administration said commonly prescribed medications expected to appear on the platform include atorvastatin, clopidogrel, lisinopril, and metformin. However, TrumpRx.gov will not include controlled substances, drugs subject to FDA-mandated risk evaluation and mitigation strategies, or medications that are not typically available through direct-to-consumer pharmacy programs.
The White House described the initiative as part of a broader effort to lower prescription drug costs and increase transparency in the healthcare system.
The announcement also highlighted several prior administration actions tied to the President’s drug pricing agenda, including the May 2025 Executive Order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” outreach to pharmaceutical manufacturers to reduce U.S. pricing disparities, and agreements intended to align American prescription drug prices with those paid in other developed countries.
The administration also referenced the February 2026 launch of TrumpRx.gov, which was initially introduced as a platform allowing cash-paying patients to directly access discounts negotiated by the administration.
